Tarsus Pharmaceuticals
TARS
105 hedge funds and large institutions have $529M invested in Tarsus Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 49 increasing their positions, 13 reducing their positions, and 12 closing their positions.
277% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 13
108% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 12
87% more call options, than puts
Call options by funds: $577K | Put options by funds: $308K
37% more capital invested
Capital invested by funds: $387M → $529M (+$142M)
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
14% more funds holding
Funds holding: 92 → 105 (+13)
11.35% more ownership
Funds ownership: 79.98% → 91.33% (+11%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$21.2M |
| 2 |
TCM
TCG Crossover Management
Palo Alto,
California
|
+$20.2M |
| 3 |
DM
Deerfield Management
New York
|
+$13.3M |
| 4 |
Millennium Management
New York
|
+$13.1M |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
+$9.18M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAC
Cowen and Company
New York
|
-$3.59M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$2.64M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$2.33M |
| 4 |
AG
Algert Global
San Francisco,
California
|
-$852K |
| 5 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$849K |
TARS Hedge Fund Activity: Q3 2023 in Review
105 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Tarsus Pharmaceuticals (TARS) for Q3 2023, worth a combined $529M — up 37% from $387M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new TARS positions and 12 closed out — a net gain of 13 holders — while 49 added to existing stakes and 13 trimmed.
The largest buyer was Cormorant Asset Management, adding an estimated $21.2M. The largest seller was Cowen and Company, cutting an estimated $3.59M.
- 105 institutional investors held Tarsus Pharmaceuticals (TARS) as of Q3 2023, up from 92 in Q2 2023.
- Funds reported $529M of Tarsus Pharmaceuticals stock for Q3 2023, up 37% quarter-over-quarter.
- 25 funds opened new Tarsus Pharmaceuticals positions in Q3 2023 and 12 closed out, a net change of +13 holders.
- The largest Tarsus Pharmaceuticals buyer in Q3 2023 was Cormorant Asset Management, an estimated $21.2M added.
- The largest Tarsus Pharmaceuticals seller in Q3 2023 was Cowen and Company, an estimated $3.59M sold.
Based on aggregated 13F filings for Q3 2023.